Press release, 13 May 2022
Today, Realheart publishes the annual report for 2021 including a report on the Company's surgeon Dilek Gürsoy and points of reference for the development plan until launch. Ina Laura Perkins writes in the CEO's statement "we took a big step forward when we left the prototype behind us to completely focus on the clinical version of our total artificial heart".
The entire annual report is available on the company's website www.realheart.se and as an appendix to this press release.
For more information please contact:
Ina Laura Perkins, CEO
Phone: +46(0)70 406 49 21
Certified Adviser: Svensk Kapitalmarknadsgranskning AB, Phone: +46 11 32 30 732, email: firstname.lastname@example.org
Scandinavian Real Heart AB develops a total artificial heart (TAH) for implantation in patients with life-threatening heart failure. Realheart® TAH has a unique, patented design that resembles that of the natural human heart. The artificial heart consists of a four-chamber system (two atria and two ventricles) designed to generate a physiological blood flow pattern that mimics the body's natural circulation. A unique concept in the medical technology world.Realheart Releases the Annual Report for 2021 in English (PDF)